Organization
Paoli Calmettes Institute
3 abstracts
Abstract
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.Org: Rouen University Hospital, Léon Bérard Cancer Center, Jean Perrin Cancer Center, Centre Eugene Marquis, Francois Baclesse Cancer Center,
Abstract
Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias.Org: Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone, Marseille, France, Institut Universitaire du Cancer Toulouse, Toulouse, France,
Abstract
Comparison of generic and specific anxiety in patients treated with apalutamide plus active surveillance vs active surveillance alone for low and intermediate risk prostate cancer.Org: Institut Paoli-Calmettes, Marseille, France, Aix-Marseille Universite, CRCM, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, IRD,